Abstract Details

Title Gray Matter and White Matter Atrophy in Patients with NMOSD Related to Disease Duration and AQP4 Positive Serostatus: Preliminary Results

Topic MS and Related Diseases

Presentation(s) P06 - (-)

Poster/Presentation
Number 122

Objective

Background BACKGROUND: Neuromyelitis optica (NMO) is a CNS autoimmune disease, with its pathogenesis related to antibodies against aquaporin-4 (AQP4ab). NMO, longitudinally extensive transverse myelitis (LETM) and optic neuritis (ON) are often referred as NMO spectrum disorders (NMOSD). So far, few studies have investigated brain structural abnormalities in this disorder.

Design/Methods DESIGN/METHODS: We analyzed 30 patients (13 NMO, 9 LETM and 8 ONr), matched to 33 controls regarding gender and age. All individuals underwent 3T MRI scan to obtain high resolution (1mm isotropic voxels) T1-weighted images. We used SPM8-DARTEL/MATLAB-R2011 to extract grey and white matter maps from each subject and perform statistical comparisons among different groups. We also investigated whether NMOSD seropositive to anti-AQP4ab (17/30) and disease duration (more than 5 years) would influence the pattern of GM/WM atrophy. We used full factorial design to compare differences among described groups, applying a threshold of p<0.001, with 50 contiguous voxels, uncorrected for multiple comparisons due to exploratory nature of this study.

Results RESULTS: ON patients presented GM atrophy (GMA) restricted to occipital lobe, while patients with LETM and NMO presented more widespread bilateral areas with GMA, encompassing frontal, parietal and occipital lobes. We also observed more widespread GMA in AQP4_positive patients and patients with longer duration (>5years). We observed white matter atrophy (WMA) restricted to chiasm and occipital lobes in ON patients; LETM patients presented brain stem WMA, while patients with NMO presented more widespread WMA in chiasm, brainstem and occipital lobes.

Conclusions CONCLUSIONS: These preliminary results revealed more diffuse GM/WM atrophy in patients with NMO and LETM, while patient with ON presented a more restricted pattern of atrophy, mainly in occipital lobes and chiasm. A more severe atrophy seems to be related to both AQP4ab seropositivity and longer disease duration.

Authors/Disclosures
Clarissa L. Yasuda, MD, PhD (University of Campinas) PRESENTER	Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for LIBBS. Prof. Yasuda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBOTT. Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for LIBBS.
Felipe Von Glehn Silva, MD, PhD, MSc, FAAN (University of Brasilia – School of Medicine)	Dr. Von Glehn Silva has nothing to disclose.
Sven O. Jarius, MD (University of Heidelberg)	Dr. Jarius has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Carlos Otavio Brandao, MD, PhD (Neurolife)	No disclosure on file
Benito P. Damasceno, MD, PhD (Neurology Department, Medical School, State University of Campinas (UNICAMP))	No disclosure on file
Brigitte Wildemann, MD (University Hospital Heidelberg, Department of Neurology)	The institution of Dr. Wildemann has received research support from Roche. The institution of Dr. Wildemann has received research support from Novartis. The institution of Dr. Wildemann has received research support from Argenx. Dr. Wildemann has received personal compensation in the range of $500-$4,999 for serving as a Conference participant with Neuraxpharm. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Speaker with Roche. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Soeaker with Instand.
Fernando Cendes, MD, PhD, FAAN (Departamento de Neurologia; FCM; UNICAMP)	Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy. The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP. The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil . The institution of Dr. Cendes has received research support from NIH.
Osama O. Zaidat, MD, FAAN (Neuroscience and Stroke Medical Director St Vincent Mercy Hospital)	Dr. Zaidat has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��